A chorus of industry stakeholders is pleading with the US FDA to prevent innovators from employing anticompetitive evergreening strategies, but the agency seems unlikely broach the subject in the near future, as action could involve a double-edged sword.
FDA panelists demonstrated serious interest at the agency's July 18 Hatch-Waxman public meeting on how to approach evergreening, which involves adjustments to approved products to extend patent life
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?